BM4SIT

AN INNOVATIVE CAUSAL THERAPY FOR ALLERGY: SAFE AND RAPID INDUCTION OF AN ANTI-INFLAMMATORY IMMUNE RESPONSE USING A MUTANT HYPOALLERGEN AND VITAMIN D3

Coordinatore	Academisch Medisch Centrum bij de Universiteit van Amsterdam    more  Organization address address: MEIBERGDREEF 9 city: AMSTERDAM postcode: 1105AZ contact info Titolo: Mr. Nome: Frank Cognome: Groen Email: send email Telefono: +31 0205663198
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	9˙589˙674 €
EC contributo	5˙996˙408 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-02-01   -   2019-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	Academisch Medisch Centrum bij de Universiteit van Amsterdam  Organization address address: MEIBERGDREEF 9 city: AMSTERDAM postcode: 1105AZ contact info Titolo: Mr. Nome: Frank Cognome: Groen Email: send email Telefono: +31 0205663198	NL (AMSTERDAM)	coordinator	1˙279˙200.00
2	HAL ALLERGY BV  Organization address address: J H OORTWEG 15 city: LEIDEN postcode: 2333 CH contact info Titolo: Mr. Nome: Coos Cognome: Bos Email: send email Telefono: +31 88 1959 025	NL (LEIDEN)	participant	2˙764˙591.00
3	BIOMAY AG  Organization address address: LAZARETTGASSE 19 city: WIEN postcode: 1090 contact info Titolo: Mr. Nome: Karl Cognome: Fister Email: send email Telefono: +43 17966 296 112 Fax: +43 1 7966 296 222	AT (WIEN)	participant	603˙364.00
4	Nome Ente NON disponibile  Organization address address: KAPITELGASSE 4-6 city: SALZBURG postcode: 5020 contact info Titolo: Ms. Nome: Doris Cognome: Stampfer Email: send email Telefono: +43 66280445011 Fax: +43 6628044745011	AT (SALZBURG)	participant	432˙840.00
5	ODENSE UNIVERSITETSHOSPITAL  Organization address address: Sdr. Boulevard 29 city: ODENSE postcode: 5000 contact info Titolo: Mr. Nome: Weber Strate Cognome: Lars Email: send email Telefono: +45 65413622	DK (ODENSE)	participant	319˙368.00
6	RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG  Organization address address: SEMINARSTRASSE 2 city: HEIDELBERG postcode: 69117 contact info Titolo: Dr. Nome: Dieter Cognome: Manthey Email: send email Telefono: +49 6221 543791	DE (HEIDELBERG)	participant	245˙160.00
7	ALL-MED SPECJALISTYCZNA OPIEKA MEDYCZNA  Organization address address: SEPIA 38 city: WROCLAW postcode: 53 143 contact info Titolo: Prof. Nome: Marek Cognome: Jutel Email: send email Telefono: +48 7134171234 Fax: +48 7134447206	PL (WROCLAW)	participant	235˙680.00
8	TURUN YLIOPISTO  Organization address address: YLIOPISTONMAKI city: TURUN YLIOPISTO postcode: 20014 contact info Titolo: Dr. Nome: Mari Cognome: Riipinen Email: send email Telefono: +358 02 3336054 Fax: +358 02 3336363	FI (TURUN YLIOPISTO)	participant	116˙205.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Allergy is the most prevalent chronic inflammatory disease, having great socio-economic impact. Chronic lifelong dependency on symptomatic drugs is an expensive reality for the vast majority of allergy sufferers. Allergen-specific immunotherapy is the only causal and effective treatment targeting the underlying immune mechanism in a more cost-effective way. Yet, long treatment duration and risk of anaphylactic side-effects have prevented this treatment from becoming the first choice. BM4SIT aims at providing an escape from its current niche position by making the treatment safer, more effective and patient friendlier, i.e. developing a therapy with negligible side-effects but improved efficacy, achieved by less injections. The concept of BM4SIT is based on two innovations: replacing current natural allergen extracts by mutated recombinant allergens having been designed to be hypo-allergenic but hyper-immunogenic, and adding an adjuvant to support rapid and effective induction of an anti-inflammatory immune response. The allergen derivative chosen to bring this concept from bench to bedside is BM4, a mutant of the culprit allergen of birch pollen allergy, Bet v 1. Pre-clinical data have demonstrated strongly reduced allergenicity, significantly increased immunogenicity and efficacy in a mouse model for birch pollen allergy. The selected adjuvant is vitamin D3, which has been shown to promote active suppression of inflammation, both in vitro and in a mouse model. The product-focused, IP-protected consortium of BM4SIT will bring BM4 and vitamin D3 to the start of Phase III clinical trials via the stages of GMP production, toxicity studies, and Phase I and II clinical trials. Addition of vitamin D3 will first be evaluated against placebo and a current product, followed by a safety and dose-range-finding study using BM4 and vitamin D3. BM4SIT will pave the way towards a better more attractive therapy that will improve the cost-benefit ratio compared to symptomatic drugs.'